S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
ASML’s Earnings Could Bring The Stock to New Highs
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
Kinder Morgan Stock Bid Up In An Oil Breakout
Undervalued UnitedHealth Group Won’t Be For Long
DocuSign and The Case for 66% Upside 
3 Computer Vision Stocks for Long-Term Gains From AI
Closing prices for crude oil, gold and other commodities
LON:MXCT

MaxCyte (MXCT) Share Price, News & Analysis

GBX 315
0.00 (0.00%)
(As of 04/16/2024 ET)
Today's Range
310.10
315
50-Day Range
312
398
52-Week Range
180
440
Volume
225 shs
Average Volume
34,370 shs
Market Capitalization
£328.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MXCT stock logo

About MaxCyte Stock (LON:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

MXCT Stock News Headlines

Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
MaxCyte earnings: here's what Wall Street expects
MaxCyte Earnings Preview
Can't believe it's happening again
One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.
MaxCyte May Benefit From Potential Gene Therapy Approval
One MaxCyte Insider Raised Stake By 400% In Previous Year
See More Headlines
Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
143
Year Founded
N/A

Profitability

Net Income
£-37,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£41.29 million
Cash Flow
GBX 157.25 per share
Book Value
GBX 223 per share

Miscellaneous

Free Float
N/A
Market Cap
£322.91 million
Optionable
Not Optionable
Beta
1.04
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Maher Masoud (Age 48)
    President, CEO, Secretary & Director
    Comp: $484.7k
  • Mr. Douglas Arthur Doerfler (Age 68)
    Founder
    Comp: $950.01k
  • Mr. Douglas J. Swirsky CFA (Age 55)
    CPA, Chief Financial Officer
  • Mr. Jay Gelfman
    Senior Vice President of Operations
  • Mr. Ronald Evan Holtz CPA (Age 66)
    Ph.D., Executive Vice President of Administration
    Comp: $514.26k
  • Mr. Sean Menarguez
    Director of Investor Relations
  • Mr. David Sandoval
    Senior Vice President & General Counsel
  • Mr. Thomas Michael Ross (Age 63)
    Executive Vice President of Global Sales
  • Mr. Jack Horgan
    Vice President of Corporate Development
  • Ms. Jill Mayer
    Senior Vice President of Human Resources

MXCT Stock Analysis - Frequently Asked Questions

How have MXCT shares performed in 2024?

MaxCyte's stock was trading at GBX 352.50 on January 1st, 2024. Since then, MXCT shares have decreased by 10.6% and is now trading at GBX 315.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of MaxCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MaxCyte investors own include boohoo group (BOO), Juno Therapeutics (JUNO), Astrotech (ASTC), Arcturus Therapeutics (ARCT), Aptose Biosciences (APTO), Appili Therapeutics (APLIF), Argan (AGX) and Applied Genetic Technologies (AGTC).

How do I buy shares of MaxCyte?

Shares of MXCT stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:MXCT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners